Rondo Therapeutics Funding: $67M Raised, Series A (2022)

Rondo Therapeutics funding overview

Rondo Therapeutics is based in San Francisco. Rondo Therapeutics has raised $67M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in March 2022. The round record for Rondo Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Red Tree Venture Capital, Canaan Partners, Johnson & Johnson Innovation – JJDC, Inc., Novo Holdings A/S, SV Health Investors. 5 distinct backers are named across the disclosed rounds.

Rondo Therapeutics at a glance

Total raised: $67M
Latest round: Series A
Latest round date: March 2022
Headquarters: San Francisco
Notable investors: Red Tree Venture Capital, Canaan Partners, Johnson & Johnson Innovation – JJDC, Inc., Novo Holdings A/S, SV Health Investors

Frequently asked about Rondo Therapeutics funding

How much has Rondo Therapeutics raised?: Rondo Therapeutics has raised $67M in total disclosed funding across the rounds on record.
Who has invested in Rondo Therapeutics?: Red Tree Venture Capital, Canaan Partners, Johnson & Johnson Innovation – JJDC, Inc., Novo Holdings A/S, SV Health Investors are named among the investors backing Rondo Therapeutics.
What was the latest Rondo Therapeutics funding round?: The most recent disclosed round is a Series A, announced in March 2022.
Where is Rondo Therapeutics based?: Rondo Therapeutics is based in San Francisco.
When did Rondo Therapeutics last raise?: The last disclosed Rondo Therapeutics round closed in March 2022 at Series A.

Rondo Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in San Francisco below to benchmark round size and investor mix.

Rondo Therapeutics Funding: $67M Raised, Series A (2022)

Rondo Therapeutics funding overview

Rondo Therapeutics at a glance

Frequently asked about Rondo Therapeutics funding

Companies related to Rondo Therapeutics (23)

Browse related funding lists (8)